Eficácia da terapia antibiótica no tratamento da infecção por clostridioides difficile em pacientes com doença inflamatória intestinal: revisão sistemática
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Clostridioides difficile infection (CDI) is a clinically relevant complication in patients
with inflammatory bowel disease (IBD), being associated with higher recurrence rates and
worse clinical outcomes, particularly in ulcerative colitis. Evidence regarding the comparative
effectiveness of antibiotics in this subgroup remains limited. This study aimed to compare the
recurrence rates and outcomes of CDI in IBD patients treated with metronidazole, vancomycin,
or fidaxomicin. A systematic review was conducted in accordance with PRISMA guidelines
and registered in PROSPERO (CRD420250491687). Searches were performed in MEDLINE,
EMBASE, PubMed, Cochrane Library, and Epistemonikos through September 2024.
Observational studies including adults with confirmed IBD and CDI treated with metronidazole
or vancomycin were eligible. Risk of bias was assessed using ROBINS-I. Outcomes included
recurrence, clinical success, colectomy, and mortality. Nine studies were included, totaling 643
patients. Of these, 235 received metronidazole and 158 vancomycin as initial therapy.
Recurrence occurred in 17.4% of metronidazole-treated patients and 8.2% of those treated with
vancomycin. A random-effects meta-analysis of four studies (n=214) yielded OR = 0.55 (95%
CI: 0.15–1.99; p = 0.36; I² = 66%), indicating no statistically significant difference, although a
trend toward lower recurrence with vancomycin was observed. Colectomy occurred exclusively
in ulcerative colitis cases, reinforcing the severity of this phenotype. Mortality was low and
similar between groups. No eligible comparative studies evaluating fidaxomicin specifically in
IBD were identified, preventing its inclusion despite its known role in reducing recurrence in
the general population. In conclusion, no statistically significant superiority between
vancomycin and metronidazole was demonstrated; however, the observed trend suggests
potential therapeutic advantage of vancomycin, particularly in patients with active colitis and
elevated recurrence risk. Heterogeneity among included studies limits definitive inferences.
Prospective, stratified clinical trials are needed to guide optimal antibiotic selection in this highrisk population.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

